Amgen Unusual Options Activity
Amgen Unusual Options Activity
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.
擁有大量資金的鯨魚對安進採取了明顯的看淡立場。
Looking at options history for Amgen (NASDAQ:AMGN) we detected 10 trades.
查看安進（NASDAQ:AMGN）期權歷史，我們檢測到10筆交易。
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 50% with bearish.
如果考慮每個交易的具體情況，就可以準確地說40%的投資者持帶看好預期的頭寸，50%持看淡預期的頭寸。
From the overall spotted trades, 2 are puts, for a total amount of $87,820 and 8, calls, for a total amount of $345,235.
從所有被發現的交易中，有2個看跌，總價值爲87820美元，有8個看漲，總價值爲345235美元。
Expected Price Movements
預期價格波動
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $270.0 to $345.0 for Amgen over the recent three months.
根據交易活動，顯然，重要的投資者正針對安進最近三個月的價格區間270.0至345.0進行瞄準。
Insights into Volume & Open Interest
成交量和持倉量分析
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 240.4 with a total volume of 1,132.00.
在流動性和興趣方面，安進期權今天的平均持倉量爲240.4，總成交量爲1132.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $270.0 to $345.0 over the last 30 days.
在下圖中，我們可以跟蹤過去30天內安進看漲和看跌期權的成交量和持倉量的發展情況，它們的執行價格範圍爲270.0至345.0。
Amgen Call and Put Volume: 30-Day Overview
安進看漲和看跌成交量：30天概述
Noteworthy Options Activity:
值得注意的期權活動：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BULLISH | 08/16/24 | $8.1 | $7.75 | $8.1 | $320.00 | $86.6K | 971 | 119 |
| AMGN | CALL | TRADE | BULLISH | 08/16/24 | $10.5 | $9.45 | $10.5 | $320.00 | $52.5K | 971 | 1 |
| AMGN | PUT | SWEEP | BEARISH | 07/19/24 | $5.05 | $4.75 | $4.93 | $317.50 | $50.3K | 80 | 0 |
| AMGN | CALL | TRADE | BEARISH | 08/16/24 | $9.6 | $9.4 | $9.4 | $320.00 | $47.0K | 971 | 65 |
| AMGN | CALL | SWEEP | BULLISH | 01/17/25 | $14.45 | $13.65 | $13.8 | $345.00 | $40.0K | 19 | 90 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看漲 | SWEEP | 看好 | 08/16/24 | $8.1 | $7.75 | $8.1 | $320.00 | $86.6K | 971 | 119 |
| AMGN | 看漲 | 交易 | 看好 | 08/16/24 | $10.5 | 9.45 | $10.5 | $320.00 | $52.5K | 971 | 1 |
| AMGN | 看跌 | SWEEP | 看淡 | 07/19/24 | $5.05 | $4.75 | $4.93 | $317.50 | $50.3K | 80 | 0 |
| AMGN | 看漲 | 交易 | 看淡 | 08/16/24 | 9.6 | 9.4美元 | 9.4美元 | $320.00 | $47.0千美元 | 971 | 65 |
| AMGN | 看漲 | SWEEP | 看好 | 01/17/25 | $14.45 | $13.65 | $13.8 | $345.00 | $40.0千美元 | 19 | 90 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
After a thorough review of the options trading surrounding Amgen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
經過對安進周邊期權交易的全面評估，我們轉而更加詳細地審查該公司。這包括對其當前的市場狀態和表現的評估。
Amgen's Current Market Status
安進當前市場狀態
- Currently trading with a volume of 869,379, the AMGN's price is down by -0.34%, now at $311.39.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 31 days.
- 成交量達869379股，安進的股價下跌了-0.34％，現在爲311.39美元。
- RSI讀數表明該股目前可能接近超買水平。
- 預期的收益發布還有31天。
Professional Analyst Ratings for Amgen
安進的專業分析師評級
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $336.0.
在過去的一個月中，有2位行業分析師分享了他們對這隻股票的見解，提出了平均目標價336.0美元。
- An analyst from RBC Capital has decided to maintain their Outperform rating on Amgen, which currently sits at a price target of $332.
- An analyst from Argus Research persists with their Buy rating on Amgen, maintaining a target price of $340.
- 摩根資本（RBC Capital）的一位分析師決定維持對安進的跑贏大盤評級，目前的股價目標爲332美元。
- 在安進上，雅運股份的一位分析師堅持買入評級，保持340美元的目標價。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期權交易具有更高的風險和潛在回報。精明的交易者通過不斷學習、調整策略、監控多個因子和密切關注市場走勢來管理這些風險。通過Benzinga Pro的實時提醒了解最新的安進期權交易。
譯文內容由第三人軟體翻譯。